Organization
Patrick Wen, MD
2 clinical trials
Clinical trial
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients With Surgically Accessible GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2024-06-30